Self-Management Interventions Using Mobile Health for the Multimorbid

September 22, 2023 updated by: University of Nebraska
The purpose of this pilot study is to evaluate the feasibility and impact of delivering mobile health self-management interventions to improve adherence to the prescribed treatment in a multimorbid population returning home after hospital discharge.

Study Overview

Detailed Description

The purpose of this three-group repeated-measures randomized controlled trial is to evaluate the use of mobile health (mHealth) self-management technology as a model of care for individuals with multimorbidity. Specifically, this 8-week self-management intervention uses tailored self-management strategies (action planning, goal setting, and individually identified support needs) and mHealth technology for real-time virtual visits, daily messages, and self-monitoring activities. The investigators are testing the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the mHealth platform (mHealth Plus). The NP evaluates physiological status by evaluating symptoms and tailoring the intervention specific to the individual's multimorbidity while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers.

The following specific aims will be addressed:

Aim 1: To evaluate the feasibility of implementing comparative SM interventions (mHealth and mHealth plus virtual visits with a nurse practitioner and community health worker team) in multimorbid individuals by assessing: a) acceptability of each intervention; b) enrollment (recruitment efficiency, attrition, problems and solutions); c) intervention fidelity (delivery, receipt, enactment of the intervention [benefits and barriers]); and d) data collection (technological transfer of data, instrument reliability, the time required, missing data).

Aim 2: To examine the impact of delivering the m-Health and m-Health plus interventions compared to standard care (SC) in multimorbid individuals on: a) primary outcome: adherence to disease-specific lifestyle behaviors (e.g. diet and medication, and self-monitoring of physiological measures as needed (e.g. weight blood pressure, blood glucose, oxygen saturation); b) secondary outcomes: health related quality of life; c) patient-reported health status; d) symptom status; and e) healthcare utilization.

Study Type

Interventional

Enrollment (Actual)

63

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nebraska
      • Lincoln, Nebraska, United States, 68588
        • University of Nebraska Medical Center, College of Nursing

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. multimorbid patients with one of 4 chronic conditions (HF, COPD, diabetes or hypertension) and have at least one other chronic disease (i.e., hypertension, cancer, stroke, heart disease, diabetes, arthritis, hepatitis, current asthma, kidney failure, or COPD),
  2. adult patients (age 19 and older)
  3. access to smart technology (phone or iPad) and internet access or a phone plan large enough for daily interactions; and d) able to hear, speak and read English.

Exclusion Criteria:

  1. major surgery while admitted;
  2. discharged to somewhere other than home (e.g., long term care facility);
  3. receiving home health services;
  4. documented dementia; and
  5. life expectancy <6 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Enhanced Usual Care
The enhanced usual care group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, individuals in the enhanced usual care group will receive the mobile health platform to record medications taken and BlueTooth devices to record physiologic measurements.
Experimental: mHealth
The mHealth group will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Subjects receive BlueTooth devices to record physiologic measurements.
The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses mobile health (m-Health) technology for daily messages and reminders to promote self-monitoring activities. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine).
Experimental: mHealth Plus
The mHealth group plus will receive evidence-based standardized disease-specific education based on discharge protocols. In addition, the mHealth plus group will receive the mobile health platform with reminders to take medications and engage in an educational tip. Participants receive BlueTooth devices to record physiologic measurements. The m-Health Plus group will receive real-time virtual visits with a nurse practitioner/community health worker team. Virtual visits are similar to an office follow-up visit with an health care provider using Zoom technology to allow for face-to-face interaction with the patient.
The intervention promotes self-management and adherence to treatment regimens in patients with multimorbidity. This 8-week SM intervention uses tailored self-management strategies (action planning, goal setting, and individual identified support needs) and mobile health (m-Health) technology for virtual visits, daily messages, and self-monitoring activities. The investigators will test the additive impact of having the nurse practitioner/community health worker (NP/CHW) team with the m-health platform. The NP will evaluate physiological and psychosocial status while the CHW will assist in recognizing possible solutions to challenging social determinants of health by identifying community resources and guidance in overcoming barriers. Bluetooth devices provided will depend on the participant's need for self-management; heart failure (scale), diabetes (glucometer), COPD (pulse oximeter) or hypertension (BP machine). Participants will receive reminders through the platform.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Usability and acceptability of the self-management interventions by administering a Usability and Acceptability tool
Time Frame: 60 days after enrolled
A Usability and Acceptability investigator developed tool.
60 days after enrolled
Enrollment of participants to the comparative self-management (SM) interventions by calculating frequency and percentage of available participants and enrolled participants.
Time Frame: 90 days after enrolled
measure of enrollment and recruitment
90 days after enrolled
Number of times the participant records activities within the application.
Time Frame: 90 days after enrollment
Measurement of engagement with the application, participant records will be downloaded from the application and frequency and percent will be calculated
90 days after enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency and percent of the participants recording a weight in pounds in the mHealth app
Time Frame: 30 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of weights recorded for heart failure participant)
30 days after intervention initiated
Frequency and percent of the participants recording a weight in pounds in the mHealth app
Time Frame: 60 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of weights recorded for heart failure participant)
60 days after intervention initiated
Frequency and percent of the participants recording a weight in pounds in the mHealth app
Time Frame: 90 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of weights recorded for heart failure participant)
90 days after intervention initiated
Frequency and percent of the participants recording a blood pressure (BP) in the mHealth app
Time Frame: 30 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of BP recorded for hypertension participant)
30 days after intervention initiated
Frequency and percent of the participants recording a blood pressure (BP) in the mHealth app
Time Frame: 60 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of BP recorded for hypertension participant)
60 days after intervention initiated
Frequency and percent of the participants recording a blood pressure (BP) in the mHealth app
Time Frame: 90 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of BP recorded for hypertension participant)
90 days after intervention initiated
Frequency and percent of the participants recording a pulse oximetry in the mHealth app
Time Frame: 30 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease. (number of oximetry readings recorded for chronic obstructive pulmonary disease (COPD) participant)
30 days after intervention initiated
Frequency and percent of the participants recording a pulse oximetry in the mHealth app
Time Frame: 60 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of oximetry readings recorded for (COPD) participant)
60 days after intervention initiated
Frequency and percent of the participants recording a pulse oximetry in the mHealth app
Time Frame: 90 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of oximetry readings recorded for the chronic obstructive pulmonary disease (COPD) participant)
90 days after intervention initiated
Frequency and percent of the participants recording a blood glucose in the mHealth app
Time Frame: 30 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of blood glucose readings recorded for the diabetic participant)
30 days after intervention initiated
Frequency and percent of the participants recording a blood glucose in the mHealth app
Time Frame: 60 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of blood glucose readings recorded for the diabetic participant)
60 days after intervention initiated
Frequency and percent of the participants recording a blood glucose in the mHealth app
Time Frame: 90 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of blood glucose readings recorded for the diabetic participant)
90 days after intervention initiated
Health related quality of life assessed by the EQ-5D-5L developed by the EuroQol group scored as an index and a visual analogue scale.
Time Frame: 30 days after intervention initiated
monitoring of physiological measures for each of the physiologic parameters appropriate for the participants chronic disease (number of blood glucose readings recorded for the diabetic participant)
30 days after intervention initiated
Health related quality of life assessed by the EQ-5D-5L developed by the EuroQol group scored as an index and a visual analogue scale.
Time Frame: 60 days after intervention initiated
Measure of quality of life
60 days after intervention initiated
Health related quality of life assessed by the EQ-5D-5L developed by the EuroQol group scored as an index and a visual analogue scale.
Time Frame: 90 days after intervention initiated
measure of quality of life
90 days after intervention initiated
Patient Reported Outcomes Measurement Information System (PROMIS®) (Promis29 V2.0) score of mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression and a visual analogue scale rating of health today
Time Frame: 30 days after intervention initiated
Measure of health status and symptoms
30 days after intervention initiated
Patient Reported Outcomes Measurement Information System PROMIS® (Promis29 V2.0) score of mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression and a visual analogue scale rating of health today
Time Frame: 60 days after intervention initiated
measure of health status and symptoms
60 days after intervention initiated
Patient Reported Outcomes Measurement Information System PROMIS® (Promis29 V2.0) score of mobility, self-care, usual activities, pain/ discomfort, anxiety/ depression and a visual analogue scale rating of health today
Time Frame: 90 days after intervention initiated
measure of health status and symptoms
90 days after intervention initiated
Emergency rooms visits and re-hospitalizations assessed by frequency and percent assessed by reviewing the electronic medical record
Time Frame: 30 days after intervention initiated
measure of health care utilization
30 days after intervention initiated
Emergency rooms visits and re-hospitalizations assessed by frequency and percent assessed by reviewing the electronic medical record
Time Frame: 60 days after intervention initiated
measure of health care utilization
60 days after intervention initiated
Emergency rooms visits and re-hospitalizations assessed by frequency and percent assessed by reviewing the electronic medical record
Time Frame: 90 days after intervention initiated
measure of health care utilization
90 days after intervention initiated

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Myra S Schmaderer, PhD, University of Nebraska

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2019

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

June 30, 2021

Study Registration Dates

First Submitted

May 4, 2020

First Submitted That Met QC Criteria

September 21, 2020

First Posted (Actual)

September 28, 2020

Study Record Updates

Last Update Posted (Actual)

September 26, 2023

Last Update Submitted That Met QC Criteria

September 22, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Chronic Conditions

Clinical Trials on mHealth intervention

Subscribe